Physicians' Academy for Cardiovascular Education

Novel diabetes drugs in clinical management: Extending the opportunities

Expert Meeting on CVD & T2DM

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME

Video navigation menu

  • Can GLP-1RAs and SGLT2 inhibitors be combined and why would we consider it? 01:05
  • Which data are available to determine when to combine the two drug classes? 02:32
  • The combination of these agents can improve glycemic control in certain patient groups 03:37
  • Which safety issues and side-effects can be expected? 04:49
  • Can these antidiabetic agents be given to non-diabetic CVD patients: the available evidence 06:14
  • Which type of patient might specifically benefit from GLP-1 RAs? 10:36

Educational information

This video was recorded during a two-day expert meeting among cardiologists and endocrinologists/internists, focussing on the topic of 'Exploring the role of GLP-1 RA in the management of CVD & T2DM'. This video reflects the discussion in the fourth of five sessions.



This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.


Funding for the Expert Meeting was provided by an unrestricted educational grant from Novo Nordisk. The sponsor did not attend and influence the meeting or the video recording.

Also see: Clinical trials in diabetes and CVD: What did we learn? Also see: What are the key mechanisms of CV benefit of novel diabetes drugs?


This is available as accredited online CME for members. Click the button below to enroll:


Share this page with your colleagues and friends: